TriCelX wins AABB accreditation for Frisco lab supporting three FDA-cleared trials

TriCelX said AABB has accredited its Frisco, Texas laboratory and granted a separate starting-material credential for the facility that makes XytriX™, the company’s experimental biotherapeutic used in three FDA-cleared trials. The move matters because the accreditation covers the lab systems that determine whether each dose is processed, stored and distributed consistently across studies in knee osteoarthritis, CTE and ALS.

Why it matters: - AABB accreditation gives TriCelX outside validation of the lab systems that make XytriX™, the biotherapeutic being tested in three FDA-cleared trials. - The credential matters because the same facility handles processing, storage and distribution for the cells used in knee osteoarthritis, CTE and ALS studies. - Consistent manufacturing is central to whether the trials can isolate the effect of the therapy from variation in the product.

What happened: - TriCelX announced that AABB accredited its laboratory at the Baylor Scott and White Sports Therapy and Research Center at The Star in Frisco, Texas. - The accreditation took effect on Sept. 30, 2026 and runs for two years, through Sept. 30, 2028. - AABB also granted TriCelX a separate Cellular Starting Material Qualification. - AABB assessors visited the site in July 2026. - The accredited laboratory processes, stores and distributes signaling cells from donated umbilical cord tissue, which are used to make XytriX™.

The details: - AABB is an international, not-for-profit association that sets standards for blood and biotherapies and evaluates whether facilities meet them. - The applicable framework is AABB’s Standards for Cellular Therapy Services, now in its 12th edition. - TriCelX’s accreditation covers named activities only and is not permanent. - The facility must be reassessed to keep the credential. - AABB concluded the lab’s quality and operational systems “meet or exceed” its requirements. - The Cellular Starting Material Qualification recognizes that TriCelX’s quality system meets AABB standards for the donated starting material before manufacturing begins. - The lab is inside a facility at The Star, the Dallas Cowboys’ world headquarters and training complex. - TriCelX’s clinical studies are run there by Dr. Abdul Baker, a board-certified neurosurgeon and the company’s chief medical and scientific officer. - AABB accredits facilities, not biotherapeutics, and has not endorsed XytriX™.

Between the lines: - The accreditation does not speak to whether XytriX™ works in patients. - It does signal that an independent body reviewed whether TriCelX can make the product the same way, every time, under documented controls. - That distinction matters more for cell-based therapies than for conventional drugs because the source material, handling and storage can affect what a patient receives. - TriCelX is trying to position XytriX™ as one platform used across multiple diseases, so manufacturing consistency becomes part of the scientific case.

What's next: - In knee osteoarthritis, dosing is already under way. - The CTE trial was cleared in June 2026. - The ALS study has now been cleared and is expected to start enrolling soon. - The first ALS participants will be dosed after the independent safety board overseeing the CTE study clears the intravenous dose. - TriCelX said work on an Alzheimer’s disease program is under way and it anticipates a pre-IND submission to the FDA in December 2026. - The company will be reassessed by AABB in two years if it wants to keep the accreditation.

The bottom line: - TriCelX now has third-party validation of the facility behind XytriX™, even as the company still has to prove the therapy itself works in human trials. - The accreditation strengthens the manufacturing story; the clinical studies still have to deliver the efficacy and safety data.